Literature DB >> 12009399

Solvent-dependent precipitation of prion protein.

Kang Cai1, Jeanette L C Miller, Christopher J Stenland, Kevin J Gilligan, Randal C Hartwell, Jarrett C Terry, Rosemary B Evans-Storms, Richard Rubenstein, Stephen R Petteway, Douglas C Lee.   

Abstract

The misfolded isoform of the prion protein (PrP(Sc)) possesses many unusual physiochemical properties. Previously, we and others reported on the differential partitioning of PrP(Sc) from plasma derived therapeutic proteins during their purification processes. To understand the driving force behind these partitioning differences, we investigated the effects of various solvent conditions on the precipitation of PrP(Sc). In a physiological buffer, PrP(Sc) remained in the supernatant after low speed centrifugation. At pH 5, PrP(Sc) precipitation was nearly complete regardless of the salt content. PrP(Sc) could also be precipitated at pH 8 by adding ethanol, but this precipitation was salt dependent. Based on these observations, an empirical mathematical model was constructed in which the PrP(Sc) precipitation trends were fully described as a function of solvent pH, salt, and ethanol concentration. This model consistently predicted PrP(Sc) partitioning during cold ethanol precipitation steps used in plasma protein purification processes, as shown by experimentally determined distributions of PrP(Sc) and transmissible spongiform encephalopathy (TSE) infectivity. These results indicate that pH, salt, and ethanol content are the major solvent factors determining the precipitation of the infectious PrP(Sc) in these processes and may provide a useful tool for assessing the differential partitioning of PrP(Sc) in a given solvent environment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009399     DOI: 10.1016/s0167-4838(02)00282-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

Review 1.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

Review 2.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

3.  Comparison of different serum sample extraction methods and their suitability for mass spectrometry analysis.

Authors:  Thamir M Alshammari; Ahmed Ali Al-Hassan; Taibi B Hadda; Mohamad Aljofan
Journal:  Saudi Pharm J       Date:  2015-02-10       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.